Francois-Xavier Frapaise, M.D has over 40 years of international drug development, regulatory ,strategic planning and marketing experience at major pharmaceutical companies including Sanofi, Bayer, Boehringer, Merck and Abbott; he has hold multiple C-level positions (CSO,CMO,CEO) in different Pharmacos in the US and Europe. Until recently ,he was heading Clinical Development, Medical Affairs and Pharmacovigilance at Merck KGaA Biosimilars Division; he has extensive experience of biosimilars development acquired at Boehringer-Ingelheim and Pfenex); his recent focus of interest is Blockchain Technology application in Pharma. He has been the CSO and SVP of Optimer, has served as the CEO of Asphelia Pharmaceuticals, Inc. VP R&D and Corporate Officer of TAP , CMO of Ocera Therapeutics, VP of Scientific Affairs at Abbott International , Head of Medical Affairs at Bayer Europe, Medical Director at Bayer France, VP of R&D at Delagrange, Head of Anti-thrombotics Strategic Marketing at Sanofi, Medical Director at Choay. Dr. Frapaise holds an M.D. degree from Faculté de Médecine Paris and is a INSEAD alumni. Dr. Frapaise holds an academic position at the Thrombosis Research Center (Loyola Medical Center in Maywood (IL). He is part of Boston-based Trestle Compliance leadership team. He now runs a consulting business, based in Paris.
